Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study

Zhuangzhuang Zheng1,2,3†, Zijing Liu1,2,3†, Haifeng Zhang4, Xiao Guo5, Xiaojing Jia6, Jianfeng Wang7, Lingbin Meng8, Ying Xin9* and Xin Jiang1,2,3*

1Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, China, 2Jilin Provincial Key Laboratory of Radiation Oncology and Therapy, Changchun, China, 3NHKLaboratory of Radiobiology, School of Public Health of Jilin University, Changchun, China, 4Department of Interventional Therapy, The First Hospital of Jilin University, Changchun, China, 5Department of Radiation Oncology, Jilin Cancer Hospital, Changchun, China, 6Department of Radiation Oncology, The Second Hospital of Jilin University, Changchun, China, 7Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, China, 8Department of Hematology and Medical Oncology, Moffitt Cancer Center, Tampa, FL, United States, 9Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, China

Background and Purpose: Apatinib is a novel antiangiogenic agent that can target vascular endothelial cell growth factor 2. The aim of our study was to evaluate the efficacy and safety of apatinib mesylate in the treatment of advanced hepatocellular carcinoma (HCC) in the real world.

Methods: We retrospectively analyzed 178 patients with advanced HCC who had been treated with apatinib mesylate from January 2017 to March 2020. The primary outcome indexes were progression-free survival (PFS) and overall survival (OS), and the secondary outcome indexes were overall response rate (ORR), disease control rate (DCR), and incidence of treatment-related adverse reactions.

Results: Univariate analysis showed that patients with third-line treatment (p < 0.001), alpha fetoprotein (AFP) ≥400 ng/ml (p < 0.05), distant metastasis (p < 0.05), portal vein tumor thrombus (PVTT) (p < 0.05), and apatinib monotherapy (p < 0.001) had shorter survival. Multivariate analysis confirmed that third-line drugs, PVTT, and combination therapy were independent prognostic factors for PFS in all patients. Univariate analysis showed that Eastern Cooperative Oncology Group (ECOG) scores (p < 0.05), line of apatinib (p < 0.001), AFP (p < 0.001), tumor progression (p < 0.05), PVTT (p < 0.05), and combination therapy (p < 0.001) had impact the OS. Multivariate analysis proved that AFP, PVTT, and combination therapy were independent prognostic factors for OS. The most common adverse reactions were secondary hypertension (29.21%), symptoms of fatigue.
**INTRODUCTION**

As one of the most common malignancies with a poor prognosis, the incidence of liver cancer continues to increase (Siegel et al., 2021). Hepatocellular carcinoma (HCC) is a major type of primary liver cancer. HCC has become an important problem affecting human health and quality of life worldwide. In China, the hepatitis B virus (HBV) is a major risk factor for primary HCC; more than 80% of primary HCC patients are HBV hepatitis B surface antigen (HBsAg)-positive (Kim et al., 2020). Besides HBV, high alpha fetoprotein (AFP), portal vein tumor thrombus (PVTT), and hepatitis C virus (HCV) also affect the prognosis of patients (Bruix et al., 2017a; Bruix et al., 20172018; Zheng et al., 2020a; Fu et al., 2020). Surgery is the preferred treatment for early primary liver cancer. Image-guided ablation, radiofrequency ablation, and microwave ablation are also applicable in the treatment of early HCC and the alternative treatment of surgery (Llovet et al., 2021). However, despite the best efforts to remove the tumor surgically, tumor recurrence still occurs in more than 50% of patients within 5 years of surgery (Heimbach et al., 2018). Outcomes of liver transplantation were considered superior than resection. However, organ shortage with prolonged waiting times plagued HCC patients, leading to tumour progression (Franssen et al., 2014). Radiotherapy can be used for HCC patients with different sizes and stages, particularly with small tumours not amenable to resection or transplantation. But radiotherapy only applied to selected patients (Wahl et al., 2016; Yang et al., 2019a). More research was needed to determine the best radiation modality and combination treatment options. Additionally, due to the insidious onset and insignificant early symptoms of HCC, most patients are diagnosed with advanced HCC. Transcatheter arterial chemoembolization (TACE) is mainly used in patients with unresectable HCC, and could effectively inhibit tumor progression (Burrel et al., 2012; Lencioni et al., 2016). However, TACE induces hypoxia in HCC tissues and increases the level of the pro-angiogenic factor, vascular endothelial growth factor (VEGF), in the remaining HCC tissues, leading to a significant neovascularization response and recurrence after treatment (Bergers et al., 2000). High VEGF receptor (VEGFR) expression promotes tumor nutrient supply, growth, metastasis, and recurrence, suggesting a poor prognosis. The previous monotherapy for first-line standard of care for patients with advanced and recurrent HCC are sorafenib and lenvatinib (Kudo et al., 2018; Benson et al., 2021). VEGF plays an important role in the occurrence and development of HCC; furthermore, drugs targeting VEGF and VEGF receptors have been used in patients with advanced HCC (Du et al., 2017). Attilizumab and antiangiogenic drugs bevacizumab have been recommended as first-line treatments for advanced HCC due to better efficacy ((Pawlik et al., 2004; Li et al., 2013; Nishikawa et al., 2013), (Pawlik et al., 2004; Li et al., 2013; Nishikawa et al., 2013). Sorafenib, a multitargeted tyrosine kinase inhibitor (TKI) and, previously, the only Food and Drug Administration (FDA)-approved, first-line-targeted drug for patients with advanced HCC (Llovet et al., 2008), extended overall survival (OS) by less than 3 months in some clinical trials (19). In the phase III randomized REFLECT trial, lenvatinib, s h owed a median OS (mOS) of 13.6 months, compared with 12.3 months in the sorafenib group (Kudo et al., 2018). Based on the results, the FDA approved lenvatinib in 2018 as the first-line treatment of patients with unresectable HCC. Regorafenib, cabozantinib, and ramucirumab are recommended as second-line systemic therapies for HCC patients who have received sorafenib treatment according to the 2021 National Comprehensive Cancer Network® (NCCN) guidelines on hepatobiliary cancers (Benson et al., 2021). In addition, based on the phase Ib/II studies, three additional treatments, namely nivolumab, pembrolizumab and ipilimumab, have been approved by the FDA after first-line treatment with sorafenib (El-Khoueiry et al., 2017; Zhu et al., 2018; Yau et al., 2020). The latest CheckMate 459 study showed that first-line nivolumab treatment (16.4 months) did not significantly improve OS compared with sorafenib (14.7 months) (Yau et al., 2022). Nivolumab might be considered as an alternative therapeutic option for patients in whom TKIs and antiangiogenic drugs are contraindicated or have risks. However, many clinical studies have shown that a considerable number of patients with HCC are not sensitive to sorafenib, and the overall efficacy is far from satisfactory (Zhu et al., 2017; Xu et al., 2020). And current therapies would cause a variety of potential adverse reactions. Therefore, we still need to discover new effective and safe drugs for HCC treatment.

Apatinib, a novel TKI, inhibits the activity of VEGFR-2 tyrosine kinase in a highly selective manner, thereby inhibiting tumor growth by inhibiting tumor angiogenesis. Apatinib can inhibit tumor cell apoptosis and cell proliferation in vitro by blocking the VEGF pathway and by inhibiting the growth of metastatic tumors in vivo (Li et al., 2018). Several clinical trials have shown that apatinib is effective in a variety of solid tumors. In China, apatinib is approved as a follow-up treatment for
patients with advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma that has progressed or relapsed after at least one round of seed system chemotherapy. In stage II and III studies, apatinib has been shown to be effective and safe in patients with gastric cancer (Zhang et al., 2017; Zheng et al., 2020b). A real world retrospective study by Zhang et al. (Zhang et al., 2017) showed that the efficacy and safety of apatinib were similar to the results of previous clinical trials. Apatinib therapy is beneficial and tolerable in patients with advanced gastric cancer who don’t respond to systemic therapy. In recent years, several studies have demonstrated its efficacy and safety in HCC, especially in patients insensitive to sorafenib (Liao et al., 2019). Apatinib increases radiosensitivity of HCC and decreases tumor growth via the suppression of the radiation-induced PI3K/AKT pathway. Additionally, combination immunization or TACE with apatinib also show good efficacy (Xu et al., 2021). TACE therapy creates an anoxic environment for the tumor, inducing high VEGFR expression and angiogenesis; this was the target attacked by apatinib. Therefore, in clinical treatment, physicians can develop an appropriate treatment combination and treatment dose based on the patient’s condition. Apatinib has been used in the treatment of advanced HCC, but its efficacy and combination therapy have not been systematically evaluated. To evaluate the efficacy and safety of apatinib in the real world, we retrospectively analyzed 178 patients with advanced HCC who had received apatinib from 2017 to 2020, and determined the influencing factors for progression-free survival (PFS) and OS. The results of this study provided a theoretical basis for the application of apatinib in patients with advanced HCC.

### PATIENTS AND METHODS

#### Patients

We screened 185 patients receiving apatinib for unresectable or relapsed HCC from the First Hospital of Jilin University, China-Japan Union Hospital of Jilin University, the Second Hospital of Jilin University, and Jilin Cancer Hospital between January 2017 and August 2020. Finally, the study included 178 eligible patients (Supplementary figure S1) The inclusion criteria were: age ≥18 years; pathological confirmation as HCC; the duration of apatinib treatment ≥1 month; at least one measurable lesion according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1; Eastern Cooperative Oncology Group performance status (ECOG) 0–2; and Child–Pugh score ≥ B. Key exclusion criteria were: other malignancies that had been diagnosed before this study; serious respiratory, cardiovascular or kidney disease; pregnant and lactating women. The study was conducted according to Good Clinical Practices and was approved by the ethics committee of the institution.

#### Ethics approval and consent to participate

All experimental protocols were approved by the Ethics Committee of the First Hospital of Jilin University. This was a retrospective study; all the patients received a normal standard treatment plan and were followed up after the treatment. No harm was caused to the patients as a result of the study procedures, therefore, the requirement for informed consent was waived.

#### Treatment

Apatinib was produced by Jiangsu Hengrui Medicine Co., Ltd (Jiangsu province) as tablets to be administered daily, orally. Patients were treated with apatinib 250 mg or 500 mg daily until disease progression or till it became intolerable. During apatinib treatment, the physicians combined TACE and immunotherapy according to the patients’ condition. Body status, blood pressure, complete blood count, and liver and kidney function were monitored during the treatment.

### TABLE 1 | Baseline characteristics of the patients treated with apatinib.

| Characteristics                  | n = 178 |
|----------------------------------|---------|
| **Sex**                          |         |
| Men                              | 146 (82.02%) |
| Women                            | 32 (17.98%)  |
| **Age**                          |         |
| <68                              | 87 (48.88%)    |
| ≥68                              | 91 (51.12%)     |
| **Tumor status**                 |         |
| Intrahepatic metastasis          | 108 (60.67%)   |
| Distant metastasis               | 44 (24.72%)    |
| Recurrence                       | 26 (14.61%)    |
| **Cancer embolus**               |         |
| Present                          | 29 (16.29%)    |
| Absent                           | 149 (83.71%)   |
| **Hepatitis (HBV/HCV)**          |         |
| Present                          | 156 (87.64%)   |
| Absent                           | 22 (12.36%)    |
| **Smoking history**              |         |
| Yes                              | 32 (17.98%)    |
| No                               | 146 (82.02%)   |
| **Hypertension history**         |         |
| Yes                              | 15 (8.43%)     |
| No                               | 163 (91.57%)   |
| **Drinking**                     |         |
| Yes                              | 33 (18.54%)    |
| No                               | 145 (81.46%)   |
| **AFP (ng/ml)**                  |         |
| <400                             | 73 (41.01%)    |
| ≥400                             | 105 (58.99%)   |
| **ECOG score**                   |         |
| 0–1                              | 142 (79.77%)   |
| 2                                | 36 (20.23%)    |
| **Child-Pugh class**             |         |
| A                                | 146 (82.02%)   |
| B                                | 32 (17.98%)    |
| **Line of apatinib**             |         |
| First-line                       | 56 (31.46%)    |
| Second-line                      | 112 (62.92%)   |
| Third-line                       | 10 (5.62%)     |
| **Drug dose**                    |         |
| 250 mg                           | 174 (97.75%)   |
| 500 mg                           | 4 (2.25%)      |
| **Combination therapy**          |         |
| Apatinib                         | 50 (28.09%)    |
| Apatinib + Immunotherapy         | 25 (14.04%)    |
| Apatinib + TACE                  | 103 (57.87%)   |

Frontiers in Pharmacology | www.frontiersin.org 3 May 2022 | Volume 13 | Article 894016
Efficacy and safety assessments
We collected the clinical and radiological data, such as tumor response, survival time, adverse reactions, combination therapy, at baseline and at 1 month after treatment initiation. Tumor response and adverse reactions were evaluated according to RECIST 1.1 and Common Terminology Criteria for Adverse Events 5.0 (CTCAE 5.0), respectively.

Data analysis
Statistical analyses were performed using SPSS version 25.0 (IBM Corp., Armonk, N.Y., United States). Categorical variables are expressed as numbers or percentages (%), and continuous variables are expressed as the mean ± standard deviation. Survival analysis was calculated using Kaplan–Meier survival curves on GraphPad Prism 8.0.1 (GraphPad Software, San Diego, California, United States). Univariate and multivariate Cox proportional hazards regression analyses were used to predict the prognostic factors for PFS and OS. A value of \( p < 0.05 \) was considered statistically significant.

RESULTS

Patients characteristics
A total of 178 patients with advanced HCC were included in this retrospective study. Patient characteristics at baseline were summarized in Table 1. Of these, 146 patients (82.02%) were male, and 32 (17.98%) were female. The median age of these patients was 58 years. The dosage of apatinib was determined by the attending physician based on the patient’s medical condition. Of the total, 174 patients (97.75%) were administered a 250 mg dosage and 4 patients (2.25%), the 500 mg dosage. Additionally, 25 patients (14.04%) were treated with apatinib in combination with immunootherapy and 103 patients (57.87%) were treated with TACE at least once during treatment with apatinib.

Efficacy of apatinib in the treatment of HCC
All patients in our efficacy analyses were treated with apatinib for at least one month. A total of 24 months of follow-up was performed. The result in Table 2 shows that complete response (CR) did not occur in any of the patients; 28 patients (15.73%) showed partial response (PR); 103 patients (57.87%) showed stable disease (SD); and 47 patients (26.40%) had progressive disease (PD). The overall response rate (ORR) was 15.73%. The disease control rate (DCR) was 73.60%. In the 28 patients with PR, 27 had 250 mg apatinib as the first/second-line treatment, and 21 patients were treated using combined immunotherapy or TACE. The Kaplan–Meier curves of total PFS (a) and OS (b) are shown in Figure 1. Patients had an overall median PFS (mPFS) of 7.0 months and an overall mOS of 16.0 months.

Prognostic factors affecting OS and PFS
We compared the survival outcomes of the different prognostic factors. Univariate analysis showed that line of apatinib (The lines of apatinib treatment), AFP, tumor progression, portal vein tumor thrombus (PVTT), and combination therapy may impact the PFS of patients. The patients without PVTT (8.0 months) showed longer mPFS compared with patients with PVTT (4.8 months) \( (p < 0.05) \) (Figure 2A). AFP level was an important factor affecting the prognosis of HCC patients. In our study, the mPFS was 8.7 months for patients with AFP<400 ng/ml and 5.0 months for patients with AFP≥400 ng/ml \( (p < 0.05) \) (Figure 2B). In addition, the mPFS was significantly longer in first-line (8.2 months) and second-line (7.0 months) treatment patients than third-line (3.1 months) \( (p < 0.001) \) (Figure 2C). Compared with apatinib monotherapy (4.4 months), the mPFS of combined therapy (combined with TACE and immunotherapy) (11.0 and 8.0 months) were longer \( (p < 0.001) \) (Figure 2D). Moreover, the mPFS was shorter in patients with distant (5.8 months) and intrahepatic metastases (7.3 months) than recurrence (11.3 months) \( (p < 0.05) \) (Figure 2E). In general, patients with third-line treatment, AFP ≥400 ng/ml, distant metastasis, PVTT, or apatinib monotherapy had shorter survival. For OS, univariate analysis showed that ECOG scores, line of apatinib, AFP, tumor progression, PVTT, and combination therapy may have impacts on it. Compared the patients with PVTT (11.0 months) with that without PVTT (16.0 months), there was significant difference in mOS between them \( (p < 0.05) \) (Figure 3A). And the mOS was 19.0 months for patients with AFP<400 ng/ml versus 12.0 months for patients with AFP≥400 ng/ml \( (p < 0.001) \) (Figure 3B). As the results showed, mOS was significantly longer in first-line (16.0 months) and second-line (17.0 months) treatment patients than in third-line (5.8 months) treatment \( (p < 0.001) \) (Figure 3C). Furthermore, the mOS of apatinib combined with TACE (20.0 months) and immunotherapy (14.0 months) were significant longer than that of apatinib monotherapy (8.7 months) \( (p < 0.001) \) (Figure 3D). The mOS also showed difference in different states of tumor progression. The mOS was shorter in patients with distant (13.0 months) and intrahepatic metastases (16.0 months) than in patients with postoperative recurrence (24.0 months) \( (p < 0.05) \) (Figure 3E). Unlike mPFS, the mOS was 16.2 months for patients with ECOG scores 0–1 versus 13.5 months for patients with ECOG scores 2 with significant difference \( (p < 0.05) \) (Figure 3F). However, according to our results, there were no significant differences in the mPFS and mOS of patients at different ages, sex, drug dose, Child–Pugh class, smoking or drinking history, and HBV/HCV status. The mPFS of patients with different ages (<58 vs. ≥58) were 7.0 and 7.3 months \( (p = 0.204) \) (Figure 4A), and the mOS were 15.0 and 16.0 months \( (p = 0.384) \) (Figure 5A), respectively.

The mPFS of patients with different sexes (man vs. woman) were

---

**TABLE 2** | Efficacy of apatinib in patients \( (n = 178) \).

| Responses                  | n (%) |
|----------------------------|-------|
| Complete response (CR)     | 0 (0%)|
| Partial response (PR)      | 28 (15.73%)|
| Stable disease (SD)        | 103 (57.87%)|
| Progressive disease (PD)   | 47 (26.40%)|
| Overall response rate (ORR)| 15.73%|
| Disease control rate (DCR) | 73.60%|

ORR: CR + PR; DCR: CR + PR + SD.
7.2 and 5.0 months ($p = 0.271$) (Figure 4B), and the mOS were 16.0 and 13.0 months ($p = 0.428$) (Figure 5B), respectively. The mPFS and mOS of patients with Child-Pugh A were 7.3 and 16.0 months, and that with Child-Pugh B were 5.0 and 13.3 months ($p = 0.787$ and $p = 0.809$) (Figures 4C, 5C). The mPFS and mOS did not show statistical differences, possibly due to the limited number of patients taking 500 mg apatinib. The mPFS of patients with different apatinib doses (250 vs. 500 mg) were 7.0 and 5.0 months ($p = 0.509$), and the mOS were 16.0 and 9.0 months ($p = 0.08$) (Figures 4D, 5D). The mPFS was 7.3 months for patients with drinking history and 6.2 months for patients without drinking history ($p = 0.883$) (Figure 5E). The mPFS and mOS was 7.3 and 16.2 months for patients with smoking history, and 6.0 and 13.0 months for patients without smoking history, without statistical difference ($p = 0.75$ and $p = 0.316$) (Figures 4F, 5F). Patients with ECOG score 0–1 had a longer mPFS than those with ECOG score 2 (8.0 vs. 5.0 months), but the results were not statistically significant ($p = 0.063$) (Figure 4G). In addition, the mPFS was 6.0 months for patients with HBV/HCV and 7.6 months for patients without HBV/HCV ($p = 0.335$) (Figure 4H). And the mOS was 12.0 months for patients with HBV/HCV and 16.0 months for patients without HBV/HCV ($p = 0.647$) (Figure 5G).

Multivariate analysis confirmed that third-line drugs (HR = 3.21; 95% confidence interval (CI), 1.54–6.68; $p < 0.05$), PVT (HR = 1.75; 95% CI, 1.13–2.70; $p < 0.05$), PTMs (HR = 1.19; 95% CI, 1.19–3.06; $p < 0.05$), and combination therapy (Apatinib + immunotherapy (HR = 1.91; 95% CI, 1.13–2.70; $p < 0.001$), particularly Apatinib + immunotherapy) were independent prognostic factors for PFS in all patients (Table 3). And multivariate analysis proved that AFP (HR = 1.61; 95% CI, 1.11–2.33; $p < 0.05$), with PVT (HR = 1.70; 95% CI, 1.05–2.74; $p < 0.05$), and combination therapy (Apatinib (HR = 4.34; 95% CI, 2.88–6.53; $p < 0.001$)) were independent prognostic factors of OS (Table 4).

**Safety of apatinib in the treatment of HCC**

Safety analysis was performed on all patients (Table 5). The most common adverse reactions were secondary hypertension (29.21%), symptoms of fatigue (16.85%), hand and foot syndrome (16.29%), vomiting (14.04%), liver dysfunction (6.18%), and proteinuria (6.74%). Of the 178 patients, 2 patients were admitted for severe diarrhea, dehydration, or bradycardia, and 1 patient was admitted for severe bone marrow suppression, which led to treatment discontinuation. The other patients had grade 1 or 2 adverse events.

**DISCUSSION**

HCC is the third leading cause of cancer death worldwide (1). Most patients with HCC are diagnosed with advanced cancer with intrahepatic or distant metastases. Multiple clinical trials have demonstrated the potential survival benefit of apatinib as first- or second-line treatment for patients with advanced HCC (Qin, 2014; Qin et al., 2021). Combinations of other antitumor therapies, including radiotherapy, immunotherapy, and TACE, can increase this survival benefit (28, 29). In this retrospective study, we investigated the safety and efficacy of apatinib in patients with advanced HCC in the real world. The mPFS and mOS of the 178 patients were 7.0 and 16.0 months, respectively. The mOS in this study was significantly higher than that of sorafenib in patients with refractory advanced HCC, as reported in previous studies (Llovet et al., 2008; Cheng et al., 2009; Bruix et al., 2012). The IMbrave150 trial showed that the mPFS in the atezolizumab plus bevacizumab group was 6.8 months, and in the sorafenib group, it was 4.3 months (Finn et al., 2020). In our study, the mPFS of apatinib monotherapy was 4.4 months, close to that of sorafenib. In the case of combined immunotherapy, mPFS reached 8.0 months, even more than atezolizumab plus bevacizumab. The mPFS was 5.7 and 5.5 months for first- and second-line treatment of unresectable HCC with apatinib in combination with camrelizumab in the RESCUE trial (29). In our study, the immune checkpoint inhibitors in immunotherapy combined apatinib included not only camrelizumab but also other drugs such as durvalumab, which may be responsible for the longer mPFS. In the RESORCE trial, regorafenib provided an OS of 10.6 months for patients with sorafenib progression, compared with a mOS.
of 8.7 months for apatinib monotherapy in our study, which was close to the efficacy of regorafenib monotherapy (Bruix et al., 2017b). The overall mPFS and mOS were significantly longer than those found in other retrospective studies involving apatinib (mPFS: 7.0 vs. 5.0 months; mOS: 16.0 vs. 13.0 months), especially as a second-line treatment; this may be due to the combination with immunotherapy (mOS: 14.0 months; mPFS: 8.0 months) or TACE (mOS: 20.0 months; mPFS: 11.0 months) in some patients in this study (Zhen et al., 2018; Qin et al., 2021). In a recent single-center retrospective study about unresectable HCC, apatinib plus camrelizumab demonstrated the mOS of 13.1 months, which was similar to our results (14.0 months) (Ju et al., 2021). Similar to other studies, apatinib combined with TACE significantly improved mPFS and mOS. In a study of combination of TACE and apatinib for the treatment of HCC, the mOS and mPFS in the combination group were

FIGURE 2 | Kaplan–Meier curves showing the PFS of patients by univariate analysis with advanced HCC treated with apatinib, including significantly different results. (A) Comparison of PFS between patients with PVTT (present) and without PVTT (absent) before the apatinib therapy. The mPFS was 4.8 months (95% CI: 3.75–5.86) for treatment with PVTT versus 8.0 months (95% CI: 7.06–8.94) for treatment without PVTT (p < 0.05). (B) Comparison of PFS between patients with AFP<400 ng/ml and AFP≥400 ng/ml before the apatinib therapy. The mPFS was 8.7 months (95% CI: 6.95–10.46) for patients with AFP<400 ng/ml versus 5.0 months (95% CI: 4.44–5.56) for patients with AFP≥400 ng/ml (p < 0.05). (C) The mPFS was significantly longer in first-line (8.2 months, 95% CI: 7.39–9.01) and second-line (7.0 months, 95% CI: 5.27–8.73) treatment patients than in third-line (3.1 months, 95% CI: 1.71–4.50) treatment (p < 0.001). (D) The mPFS of apatinib combined with TACE (11.0 months, 95% CI: 8.32–13.66) and immunotherapy (8.0 months, 95% CI: 6.53–9.47) was longer than that of apatinib monotherapy (4.4 months, 95% CI: 3.63–5.17) (p < 0.001). (E) The mPFS was shorter in patients with distant (5.8 months, 95% CI: 4.50–7.10) and intrahepatic metastases (7.3 months, 95% CI: 4.97–9.63) than in patients with postoperative recurrence (11.3 months, 95% CI: 6.50–16.10) (p < 0.05), compared with different states of tumor progression.
only 10.0 and 5.5 months, lower than the 20.0 and 11.0 months in our study (Liu et al., 2021). In their study, most HCC was accompanied by vascular invasion or distant metastasis, which were the important factors impairing the prognosis of patients (Yang et al., 2019b). The promising efficacy of apatinib may be due to its ability to selectively target VEGFR-2 and a higher binding affinity than sorafenib. TACE induces hypoxia in HCC tissues and increases the level of VEGF in the remaining HCC tissues, leading to a significant neovascularization response (Tian et al., 2011). Therefore,

FIGURE 3 | Kaplan–Meier curves showing the OS of patients by univariate analysis with advanced HCC treated with apatinib, including significantly different results. (A) Comparison of OS between patients with PVTT (present) and without PVTT (absent) before the apatinib therapy. The mOS was 11.0 months (95% CI: 8.90–13.10) for treatment with PVTT versus 16.0 months (95% CI: 13.42–18.58) for treatment without PVTT (p < 0.05). (B) Comparison of OS between patients with AFP<400 ng/ml and AFP≥400 ng/ml before the apatinib therapy. The mOS was 19.0 months (95% CI: 16.74–21.26) for patients with AFP<400 ng/ml versus 12.0 months (95% CI: 10.72–13.28) for patients with AFP≥400 ng/ml (p < 0.001). (C) The mOS was significantly longer in first-line (16.0 months, 95% CI: 12.61–19.39) and second-line (17.0 months, 95% CI: 14.33–19.67) treatment patients than in third-line (5.8 months, 95% CI: 0.64–10.97) treatment (p < 0.001). (D) The mOS of apatinib combined with TACE (20.0 months, 95% CI: 17.13–22.88) and immunotherapy (14.0 months, 95% CI: 12.58–15.42) was longer than that of apatinib monotherapy (8.7 months, 95% CI: 6.51–10.90) (p < 0.001). (E) The mOS was shorter in patients with distant (13.0 months, 95% CI: 10.09–15.91) and intrahepatic metastases (16.0 months, 95% CI: 12.54–19.46) than in patients with postoperative recurrence (24.0 months, 95% CI: 18.54–29.46) (p < 0.05), compared with different states of tumor progression. (F) Comparison of OS between patients with ECOG scores 0–1 and 2 before the apatinib therapy. The mOS was 16.2 months (95% CI: 13.33–19.07) for patients with ECOG scores 0–1 versus 13.5 months (95% CI: 10.39–16.61) for patients with ECOG scores 2 (p < 0.05).
the combination of apatinib and TACE can improve the efficacy.

In univariate analysis, there were no significant differences in mPFS and mOS between patients with different ages, sex, drug dose, Child–Pugh class, smoking or drinking history, and HBV/HCV status. Patients with ECOG score 0–1 had a longer mPFS than those with ECOG score 2, but the results were not statistically significant; meanwhile, different ECOG scores had a significant impact on mOS. HBV/HCV infection and drinking showed no influence on patients’ survival, which may be because viral infection and alcohol consumption are the pathogenic factors of HCC, and antiviral therapy and alcohol abstention are carried out after the diagnosis of HCC (Chong et al., 2015). The effect of HBV/HCV on the prognosis of HCC patients may be related to the treatment mode, and the current research is controversial (Papatheodoridi et al., 2021). It has been reported that in a population of HCC patients undergoing surgical resection, the presence or absence of HBV/HCV infection has no effect on patient prognosis (Pawlik et al., 2004; Li et al., 2013; Nishikawa et al., 2013). This result was interpreted as tumors in patients with HBV/HCV infection were more likely to form an envelope, limiting tumor growth (Pawlik et al., 2004; Li et al., 2013; Nishikawa et al., 2013). Previous studies have also shown that the presence of HBV/HCV in patients with advanced HCC does not adversely affect the efficacy of apatinib or sorafenib, but may even be beneficial to it (3). 60–90% of HCCs develop in persons with basic liver disease, which may lead persons to stop consuming alcohol and smoking, and may bias the true association (Turati et al., 2014; Petrick et al., 2018). Since only 4 patients received the 500 mg dose, with no significant survival difference, they were excluded from the multivariate analysis to avoid bias. In this retrospective study, AFP, PVTT, and combination therapy were identified as independent prognostic factors for OS, while line of apatinib, PVTT, and combination therapy were independent prognostic factors for PFS.

Among all patients, mPFS was significantly longer in first-line and second-line treatment patients than in third-line treatment patients, suggesting that earlier application of apatinib for HCC may lead to better survival (Qin, 2014). In the 28 patients with PR, 27 had 250 mg of apatinib as their first/second-line treatment. Early application of apatinib had better antitumor effect. However, there was no difference in survival between first-line and second-line treatment groups; this may be related to the choice of combination therapy. Unfortunately, although univariate analysis showed that different line of apatinib had an effect on the OS of patients with advanced HCC, Cox
Regression analysis did not show the same results. Extrahepatic metastasis is a known risk factor for patients with HCC, and this was supported by the results of the univariate analysis. AFP level and PVTT were considered important factors affecting the survival and prognosis of patients with HCC (Tandon and Garcia-Tsao, 2009). In our study, patients with AFP ≥ 400 ng/ml had 1.61-fold the risk of death compared with patients with AFP < 400 ng/ml, while patients with PVTT had a 1.75-fold and 1.70-fold risk of progression and death, respectively, compared with patients without PVTT. In contrast, survival and prognosis were significantly worse in patients with venous PVTT, which is consistent with previous studies (3, 49).

Our study confirmed that apatinib combined with immunotherapy or TACE can significantly improve efficacy. In the 28 patients with PR, 21 patients were treated with apatinib combined with immunotherapy or TACE. Especially for patients with PVTT, apatinib combined with TACE has a longer survival

---

**TABLE 3 | Multivariable Cox proportional hazard models of progression.**

| Covariate | HR (95%CI) | p value |
|-----------|------------|---------|
| Line of apatinib | – | – |
| First-line | – | – |
| Second-line | 1.19 (0.84,1.69) | 0.327 |
| Third-line | 3.21 (1.54,6.68) | 0.002 |
| PVTT | – | – |
| Absent | – | – |
| Present | 1.75 (1.13,2.70) | 0.011 |
| Combination therapy | – | – |
| Apatinib | 3.70 (2.48,5.52) | <0.001 |
| Apatinib + immunotherapy | 1.91 (1.19,3.06) | 0.008 |
| Apatinib + TACE | – | – |

**TABLE 4 | Multivariable Cox proportional hazard models of mortality.**

| Covariate | HR (95%CI) | p value |
|-----------|------------|---------|
| AFP LR | – | – |
| <400 ng/ml | – | – |
| ≥400 ng/ml | 1.61 (1.11,2.33) | 0.012 |
| PVTT | – | – |
| Absent | – | – |
| Present | 1.70 (1.06,2.74) | 0.032 |
| Combination therapy | – | – |
| Apatinib | 4.34 (2.88,6.53) | <0.001 |
| Apatinib + immunotherapy | 1.62 (0.94,2.81) | 0.086 |
| Apatinib + TACE | – | – |
than TACE alone (Fan et al., 2019). Numerous clinical studies have corroborated the benefits of TACE plus apatinib for advanced HCC. TACE therapy can create an anoxic environment for the tumor, which induces high VEGFR expression and angiogenesis; this is why the combination with apatinib is so effective (Pinato et al., 2018). Recently, the RESCUE trial showed that apatinib therapy combined with camrelizumab was controllable, safe, and showed a good curative effect in advanced HCC (Xu et al., 2021). The ORR was 34.3% in the first-line and 22.5% in the second-line cohort. mPFS in the cohorts were 5.7 and 5.5 months, respectively. Meanwhile, the mPFS of patients with HCC treated with combination immunotherapy was 8.0 months, which may be due to the use of multiple immunotherapy drugs, including carrelizumab and attilizumab, in our enrolled patients.

Apatinib, similar to other molecularly targeted drugs, can cause adverse reactions; this was a focus of the current study as well. Detailed information regarding this is shown in Table 5. The most common adverse reactions were secondary hypertension (29.21%), symptoms of fatigue (16.85%), hand and foot syndrome (16.29%), vomiting (14.04%), liver dysfunction (6.18%), and proteinuria (6.74%). These adverse reactions could be tolerated or were alleviated with symptomatic treatment. Of the 178 patients, 2 patients were admitted for severe diarrhea, dehydration, proteinuria, or bradycardia, and 1 patient was admitted for severe bone marrow suppression, which led to treatment discontinuation. The other patients experienced grade 1 or 2 adverse events. Hypertension, proteinuria, and reduced liver function were more common in the apatinib treatment group, while sorafenib was more likely to cause hand-foot syndrome (Zhao et al., 2016). The adverse effects of apatinib are relatively mild compared to other cytotoxic chemotherapies and targeted therapies. No deaths associated with apatinib treatment or irreversible organ or tissue damage were observed in our study. However, possible adverse reactions associated with apatinib still require further study.

This study had some limitations. First, this was a retrospective pilot study with patients from Jilin, Liaoning, Heilongjiang, and Inner Mongolia provinces. Second, the doses of apatinib taken by patients were mostly 250 mg, which was determined by the physician based on weight, general condition, and tolerability; it was significantly lower than the doses used in previous studies on gastric and breast cancer. Only 4 patients in this study received the 500 mg dose, therefore, it was difficult to elucidate the differences between the effects at various doses. Third, both HBV and HCV are important pathogenic factors of HCC, however, we did not analyze the two factors separately. Fourth, this is a single-arm study with a small sample size, and large randomized controlled trials are still needed to explore the efficacy and safety of apatinib for advanced HCC.

**CONCLUSION**

The result of our study suggested that apatinib is effective in treating advanced HCC. Apatinib combined with TACE or immunotherapy increased the survival benefit for patients with advanced HCC. The most common adverse reactions occurred in patients were secondary hypertension, gastrointestinal resistance, symptoms of fatigue, and hand and foot syndrome, which were tolerable and manageable.

**DATA AVAILABILITY STATEMENT**

All data generated or analyzed during this study are included in this published article. The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the ethical committee of the First Hospital of Jilin University (NO. 2020-687). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

---

**TABLE 5 | All adverse reactions in the patients after taking apatinib.**

| Grade, n (%) | Grades 1 (%) | Grades 2 (%) | Grades 3 (%) | Grades 4 (%) | Grades 5 (%) |
|-------------|--------------|--------------|--------------|--------------|--------------|
| Vomiting    | 12 (6.74%)   | 13 (7.30%)   | 0            | 0            | 0            |
| Increased ALT/AST | 5 (2.81%)  | 7 (3.93%)    | 0            | 0            | 0            |
| Proteinuria | 3 (1.69%)    | 8 (4.49%)    | 0            | 0            | 0            |
| Fatigue     | 20 (11.24%)  | 10 (5.62%)   | 0            | 0            | 0            |
| Hypertension| 9 (5.06%)    | 43 (24.16%)  | 0            | 0            | 0            |
| Decreased platelet | 3 (1.69%) | 6 (3.37%)    | 1 (0.56%)    | 0            | 0            |
| Hand and foot syndrome | 10 (5.62%) | 19 (10.67%) | 0            | 0            | 0            |
| Diarrhea    | 4 (2.25%)    | 11 (6.18%)   | 1 (0.56%)    | 0            | 0            |
| Hoarseness  | 3 (1.69%)    | 2 (1.12%)    | 0            | 0            | 0            |
| Rash        | 5 (2.81%)    | 3 (1.69%)    | 0            | 0            | 0            |
| Bradycardia | 0            | 0            | 1 (0.56%)    | 0            | 0            |
| Alopecia    | 2 (1.12%)    | 0            | 0            | 0            | 0            |
| Headache    | 2 (1.12%)    | 0            | 0            | 0            | 0            |
| Gastrointestinal hemorrhage | 0           |              | 1 (0.56%)    | 0            | 0            |

ALT/AST, alanine aminotransferase/aspartate aminotransferase; Hypertension, the hypertension here was defined as an increase in blood pressure compared to before apatinib.
AUTHOR CONTRIBUTIONS

Conceptualization, XJ and YX; Software, XG; Validation, XJ and YX; Formal Analysis, ZZ; Investigation, ZL, XG, XJJ, and JW; Resources, XJ; Data Curation, ZZ; Writing-Original Draft Preparation, ZZ, ZL, and XG; Writing-Review and Editing, LM, YX, and XJ; Funding Acquisition, YX and XJ. All authors read and approved the manuscript.

FUNDING

This research was supported by the Jilin Provincial Science and Technology Foundations (Grant Number 20210509003RQ and 20210402002G), the Achievement Transformation Guiding Foundations of First Hospital of Jilin University (Grant Number CGZHYD202012-029).

ACKNOWLEDGMENTS

We would like to thank Editage (www.editage.cn) for English language editing.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.894016/full#supplementary-material

REFERENCES

Benson, A. B., D’Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Arc, C., et al. (2021). Hepatobiliary Cancers, Version 2.2021. NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc Netw. 19 (5), 541–565.
Berger, C., Brekken, R., McMahon, G., Vu, T. H., Tamaki, K., et al. (2000). Matrix Metalloproteinase-9 Triggers the Angiogenic Switch during Carcinogenesis. Nat. Cell Biol. 2 (10), 737–744. doi:10.1038/35063674
Bruix, J., Cheng, A.-L., Meinhardt, G., Nakajima, K., De Sanctis, Y., and Llovet, J. (2017). Corrigendum to "Prognostic Factors and Predictors of Sorafenib Benefit in Patients with Hepatocellular Carcinoma: Analysis of Two Phase III Studies" [J Hepatol 67 (2017) 999-1008]. J. Hepatol. 69 (4), 999990–999991. doi:10.1016/j.jhep.2018.07.015
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y. H., Bodoky, G., et al. (2017). Regorafenib for Patients with Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet 389 (10064), 56–66. doi:10.1016/S0140-6736(16)32453-9
Bruix, J., Raoul, J. L., Sherman, M., Mazzaferrro, V., Bolondi, L., Craxi, A., et al. (2012). Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Subanalyses of a Phase III Trial. J. Hepatol. 57 (4), 821–829. doi:10.1016/j.jhep.2012.06.014
Bruix, J., Cheng, A.-L., Meinhardt, G., Nakajima, K., De Sanctis, Y., and Llovet, J. (2017). Prognostic Factors and Predictors of Sorafenib Benefit in Patients with Hepatocellular Carcinoma: Analysis of Two Phase III Studies. J. Hepatol. 67 (5), 999–1008. doi:10.1016/j.jhep.2017.06.026
Burrel, M., Reig, M., Forner, A., Barrufet, M., de Lope, C. R., Tremosini, S., et al. (2012). Survival of Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolisation (TACE) Using Drug Eluting Beads. Implications for Clinical Practice and Trial Design. J. Hepatol. 56 (6), 1330–1335. doi:10.1016/j.jhep.2012.01.008
Cheng, A. L., Kang, Y. K., Chen, Z., Tsao, C. J., Qin, S., Kim, J. S., et al. (2009). Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: a Phase III Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Oncol. 10 (1), 25–34. doi:10.1016/S1470-2045(08)70285-7
Chong, C. C., Wong, G. L., Wong, V. W., Ip, P. C., Cheung, Y. S., Wong, J., et al. (2015). Antiviral Therapy Improves post-hepatectomy Survival in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: a Prospective-Retrospective Study. Aliment. Pharmacol. Ther. 41 (2), 199–208. doi:10.1111/apt.13034
Du, H., Zhao, J., Hai, L., Wu, J., Yi, H., and Shi, Y. (2017). The Roles of Vasohibin and its Family Members: Beyond Angiogenesis Modulators. Cancer Biol. Ther. 18 (11), 827–832. doi:10.1080/15384407.2017.1373217
El-Khoueiry, A. B., Sangro, B., Yao, T., Crocenzi, T. S., Kudo, M., Hsu, C., et al. (2017). Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): an Open-Label, Non-comparative, Phase 1/2 Dose Escalation and Expansion Trial. Lancet 389 (10088), 2492–2502. doi:10.1016/S0140-6736(17)31046-2
Fan, W., Yuan, G., Fan, H., Li, F., Wu, Y., Zhao, Y., et al. (2019). Apatinib Combined with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. Clin. Ther. 41 (8), 1463–1476. doi:10.1016/j.clinthera.2019.04.036
Fin, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducrueix, M., Kim, T. Y., et al. (2020). Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 382 (20), 1894–1905. doi:10.1056/NEJMoa1915745
Franessen, B., Jibara, G., Tabrizian, P., Schwartz, M. E., and Roayaie, S. (2014). Actual 10-year Survival Following Hepatectomy for Hepatocellular Carcinoma. HPB (Oxford) 16 (9), 830–835. doi:10.1111/hip.12206
Fu, N., Du, H., Li, D., Lu, Y., Li, W., Wang, Y., et al. (2020). Clusterin Contributes to Hepatitis C Virus-Related Hepatocellular Carcinoma by Regulating Autophagy. Life Sci. 256, 117911. doi:10.1016/j.lfs.2020.117911
Hemibeck, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., et al. (2018). AASLD Guidelines for the Treatment of Hepatocellular Carcinoma. Hepatology 67 (1), 358–380. doi:10.1002/hep.29086
Ju, S., Zhou, C., Yang, C., Wang, C., Liu, J., Wang, Y., et al. (2021). Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center. Front. Oncol. 11, 835889. doi:10.3389/fonc.2021.835889
Kim, G. A., Han, S., Choi, G. H., Choi, J., and Lim, Y. S. (2020). Moderate Levels of Serum Hepatitis B Virus DNA Are Associated with the Highest Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients. Aliment. Pharmacol. Ther. 51 (11), 1169–1179. doi:10.1111/apt.15725
Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., et al. (2018). Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: a Randomised Phase 3 Non-inferiority Trial. Lancet 391 (10126), 1163–1173. doi:10.1016/S0140-6736(18)30207-1
Lencioni, R., de Baere, T., Soulen, M. C., Rilling, W. S., and Geschwind, J. F. (2016). Lipiodol Transarterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review of Efficacy and Safety Data. Hepatology 64 (1), 106–116. doi:10.1002/hep.28453
Li, T., Qin, L. X., Gong, X., Zhou, J., Sun, H. C., Qiu, S. J., et al. (2013). Hepatitis B Virus Surface Antigen-Negative and Hepatitis C Virus Antibody-Negative Hepatocellular Carcinoma: Clinical Characteristics, Outcome, and Risk Factors for Early and Late Intrahepatic Recurrence after Resection. Cancer 119 (1), 126–135. doi:10.1002/cncr.27697
Li, X., Xu, A., Li, H., Zhang, B., Cao, B., and Huang, J. (2018). Novel Role of Apatinib as a Multi-Target RTK Inhibitor in the Direct Suppression of Hepatocellular Carcinoma Cells. Biochim. Biophys. Acta Mol. Basis Dis. 1864 (5 Pt A), 1693–1701. doi:10.1016/j.bbadis.2018.02.014
Liao, J., Jin, H., Li, S., Xu, L., Peng, Z., Wei, G., et al. (2019). Apatinib Potentiates Irradiation Effect via Suppressing PI3K/AKT Signaling Pathway in
Hepatocellular Carcinoma. J. Exp. Clin. Cancer Res. 38 (1), 454. doi:10.1186/s13046-019-1419-1

Liu, S., Liu, K. C., Lv, W. F., Lu, D., Zhu, X. H., Jiang, B., et al. (2021). The Efficacy and Prognostic Factors of the Combination of TACE and Apatinib for the Treatment of BCLC Stage C Hepatocellular Carcinoma. Front. Med. (Lausanne) 8, 774345. doi:10.3389/fmed.2021.774345

Llövet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., et al. (2021). Apatinib in Advanced Hepatocellular Carcinoma. Nat. Rev. Dis. Primers 7 (1), 6. doi:10.1038/s41572-020-00240-3

Llövet, J. M., Ricci, S., Mazzaferrro, V., Hilgard, P., Gane, E., Blanc, J. F., et al. (2008). Apatinib in Chinese Patients with Advanced Hepatocellular Carcinoma: A Phase II Randomized, Open-Label Trial. J. Clin. Oncol. 26, 1003–1012. doi:10.1200/jco.2007.14.1934

Nishikawa, H., Arimoto, A., Wakasa, T., Kita, R., Kimura, T., and Osaki, Y. (2013). Pinato, D. J., Pai, M., Reccia, I., Patel, M., Giakoustidis, A., Karamanakos, G., et al. (2016). Outcomes after Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J. Clin. Oncol. 34 (5), 452–459. doi:10.1200/jco.2015.61.4925

Xu, J., Ji, L., Liang, Y., Wan, Z., Zheng, W., Song, X., et al. (2020). CircRNA-SORE Mediates Sorafenib Resistance in Hepatocellular Carcinoma by Stabilizing YBX1. Signal. Transduct Target. Ther. 5 (1), 298. doi:10.3389/srtt.2020.00037-5

Xu, J., Shen, J., Gu, S., Zhang, Y., Wu, L., Wu, J., et al. (2021). Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Randomized, Open-Label, Phase II Trial. Clin. Cancer Res. 27 (4), 1003–1011. doi:10.1158/1078-0432.CCR-20-2571

Yang, J. F., Lo, C. H., Lee, M. S., Lin, C. S., Dai, Y. H., Shen, P. C., et al. (2019). Stereotactic Ablative Radiotherapy versus Conventionally Fractionated Radiotherapy in the Treatment of Hepatocellular Carcinoma with portal Vein Invasion: a Retrospective Analysis. Radiat. Oncol. 14 (1), 180. doi:10.1186/s13046-019-1382-1

Yau, T., Kang, Y. K., Kim, T. Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., et al. (2020). Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 6 (11), e204564. doi:10.1001/jamaoncol.2020.4561

Yau, T., Park, J. W., Finn, R. S., Cheng, A. L., Mathurin, P., Edeline, J., et al. (2022). Nivolumab versus Sorafenib in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomized, Multicentre, Open-Label, Phase 3 Trial. Lancet Oncol. 23 (1), 77–90. doi:10.1016/s1470-2045(21)00664-5

Zhang, Y., Han, C., Li, J., Zhang, L., Wang, L., Ye, S., et al. (2017). Efficacy and Safety for Apatinib Treatment in Advanced Gastric Cancer: a Real World Study. Sci. Rep. 7 (1), 13208. doi:10.1038/s41598-017-13192-8

Zheng, Y., Yang, X., Yan, C., Feng, R., Sah, B. K., Yang, Z., et al. (2020). Effect of Apatinib Plus Neoadjuvant Chemotherapy Followed by Resection on Pathologic Response in Patients with Locally Advanced Gastric Adenocarcinoma: A Single-Arm, Open-Label, Phase II Trial. Eur. J. Cancer 139 (4), 928–937. doi:10.1016/j.ejca.2020.02.013

Zhen, L., Jiali, C., Yong, F., Han, X., Hongming, P., and Weidong, H. (2018). The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or Relapsed Liver Cancer: a Retrospective Study. J. Cancer 9 (16), 2773–2777. doi:10.7150/jca.26376

Zheng, Y., Yang, X., Yan, C., Feng, R., Sah, B. K., Yang, Z., et al. (2020). Effect of Apatinib Plus Neoadjuvant Chemotherapy Followed by Resection on Pathologic Response in Patients with Locally Advanced Gastric Adenocarcinoma: A Single-Arm, Open-Label, Phase II Trial. Eur. J. Cancer 130, 12–19. doi:10.1016/j.ejca.2020.02.013

Zheng, Y., Zhu, M., and Li, M. (2020). Effects of Alpha-Fetoprotein on the Occurrence and Progression of Hepatocellular Carcinoma. J. Cancer Res. Oncol. 146 (10), 2439–2446. doi:10.1007/s00432-020-03331-6

Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., et al. (2018). Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-randomised, Open-Label Phase 2 Trial. Lancet Oncol. 19 (7), 940–952. doi:10.1016/S1470-2045(18)30351-6

Zhu, Y. J., Zheng, B., Wang, H. Y., and Chen, L. (2017). New Knowledge of the Mechanisms of Sorafenib Resistance in Liver Cancer. Acta Pharmacol. Sin. 38 (5), 614–622. doi:10.1038/aps.2017.5

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zheng, Liu, Zhang, Guo, Jia, Wang, Meng, Xin and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.